The University of Chicago Header Logo

Connection

David Rubin to Injections, Subcutaneous

This is a "connection" page, showing publications David Rubin has written about Injections, Subcutaneous.
Connection Strength

0.170
  1. Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial. J Crohns Colitis. 2026 May 08; 20(5).
    View in: PubMed
    Score: 0.058
  2. Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2026 04; 11(4):284-298.
    View in: PubMed
    Score: 0.057
  3. Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials. Lancet. 2025 07 26; 406(10501):358-375.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.